NCT00317850

Gabapentin for the Treatment of Tinnitus

Gabapentin for the Relief of Idiopathic Subjective Tinnitus

• Status: Terminated
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 160 (planned)
• Sponsor: Washington University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The specific aim of the Gabapentin for the Relief of Idiopathic Subjective Tinnitus Trial is to assess the therapeutic benefit of Gabapentin (Neurontin®) for subjective idiopathic troublesome tinnitus. We employed a double-blind placebo-controlled randomized clinical trial design to assess the efficacy of Gabapentin. Adults, between the ages of 18 and 70 with idiopathic, subjective, troublesome, unilateral or bilateral, non-pulsatile tinnitus of 6 month's duration or greater and score of 38 or greater on the Tinnitus Handicap Inventory were enrolled.

Conditions

• Tinnitus

Interventions

Type	Name	Description
DRUG	Gabapentin (Neurontin)

Timeline

• Start date: 2004-04-01
• Completion: 2006-02-01
• First posted: 2006-04-25
• Last updated: 2012-03-02